Other News To Note
Alchemia Ltd., of Brisbane, Australia, said it randomized the first patient in its pivotal Phase III study of HA-Irinotecan, its lead cancer drug that uses the firm's HyACT technology to target irinotecan directly to cancer cells.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter